TrialA Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
Trial details
- Registry ID
- NCT04126473
- Phase
- Phase 2
ELOX
Eloxx Pharmaceuticals, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleNCT04126473 | ELOX | Phase 2 | Completed | 2022-04-06Actual |
| A Study of ELX-02 in Patients With Alport SyndromeNCT05448755 | ELOX | Phase 2 | Completed | 2023-09-11Actual |
| EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and SafetyNCT07523581 | ELOX | Phase 2 | Recruiting | 2027-06-30Estimated |
A Study of ELX-02 in Patients With Alport Syndrome
Trial details
- Registry ID
- NCT05448755
- Phase
- Phase 2
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
Trial details
- Registry ID
- NCT07523581
- Phase
- Phase 2
Latest recorded trial changes
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581 · Eloxx Pharmaceuticals, Inc.
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting
A Study of ELX-02 in Patients With Alport Syndrome
NCT05448755 · Eloxx Pharmaceuticals, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: The incidence and characteristics of adverse events
+ After
Measure: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
8 participants (planned)
+ After
3 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
30 May 2023
+ After
11 Sep 2023
Recruitment status changed
− Before
Recruiting
+ After
Completed